FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   SEDLACK STUART D 2. Date of Event Requiring Statement (Month/Day/Year) 07/12/2011 3. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [AMRN] (Last) (First) (Middle) C/O AMARIN PHARMA, INC., MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Senior Vice President 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) MYSTIC, CT 06355 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	  (2)	04/20/2020	Ordinary Shares (1)	127,500	$ 1.7	D	Â
Stock Option (right to buy)	  (3)	03/16/2021	Ordinary Shares (1)	200,000	$ 7.19	D	Â
Stock Option (right to buy)	  (4)	05/23/2021	Ordinary Shares (1)	205,000	$ 18.77	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SEDLACK STUART D C/O AMARIN PHARMA, INC. MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE MYSTIC, CT 06355	Â	Â	  Senior Vice President	Â

Signatures

/s/ Frederick Ahlholm, by power of attorney		07/14/2011
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)	On April 20, 2010, the reporting person was granted an option under the Amarin Corporation plc 2002 Stock Option Plan. The stock option initially vested in four equal installments on each anniversary of such grant date. In December 2010, the Issuer's Board of Directors approved the acceleration of the vesting of this award by six months such that the option vests in four equal installments and will be fully vested on October 20, 2013.
(3)	On March 16, 2011, the reporting person was granted an option under the Amarin Corporation plc 2002 Stock Option Plan. The stock option will vest in four equal installments on each anniversary of such grant date.
(4)	On May 23, 2011, the reporting person was granted an option under the Amarin Corporation plc 2002 Stock Option Plan. The stock option will vest in four equal installments on each anniversary of such grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.